Key result
Local PDE3 antagonist amrinone increases the lipolytic response to hypoglycemia ~9-fold versus control.
Why the study?
The role of phosphodiesterase type 3 in regulating in vivo lipolysis in human adipose tissue during simultaneous insulin and catecholamine stimulation was unclear.
Does local administration of the PDE 3 antagonist amrinone alter the lipolytic response in adipose tissue during insulin-induced hypoglycemia in healthy subjects?
Does local administration of the PDE 3 antagonist amrinone alter the lipolytic response in adipose tissue during insulin-induced hypoglycemia in healthy subjects?
PDE 3 activation counteracts the lipolytic effect of catecholamines during insulin-induced hypoglycemia, and its specific blockade greatly increases lipolysis in human adipose tissue.
Answers are grounded in this paper and cite their sources.
PDE3 blockade augments lipolysis during hypoglycemia; hypothesis-generating for metabolic regulation studies.
The present investigation aimed to clarify the role of phosphodiesterase (PDE) type 3 for in vivo lipolysis in human adipose tissue during simultaneous insulin and catecholamine stimulation. Therefore, ten healthy subjects were investigated during insulin-induced hypoglycemia. Microdialysis probes were implanted in the subcutaneous adipose tissue and perfused by solvents with or without addition of the specific PDE 3 antagonist amrinone. Furthermore, changes in the local blood flow surrounding the dialysis probes were assessed by the ethanol escape technique. During the 60 min period before the start of the insulin infusion, adipose tissue glycerol levels (lipolysis index) increased significantly when amrinone was added to the perfusate (p = 0.0006, one-factor ANOVA). The antilipolytic response to the early phase of insulin infusion decreased (delta glycerol 9.0+/-3.5 vs. 29.9+/-6.0 micromol/l, p = 0.04) and the lipolytic response after hypoglycemia increased (AUC 122.4+/-18.0 vs. 13.4+/-16.3 micromol x l(-1) x h, p = 0.0001) comparing the experiments with or without amrinone, respectively. When amrinone was excluded from the perfusate, there was an increase in the nutritive blood flow during hypoglycemia, whereas there were no significant changes in the local blood flow surrounding the probe when amrinone was added to the perfusate. In conclusion, during insulin-induced hypoglycemia, PDE 3 activation clearly counteracts the lipolytic effect of catecholamines. When PDE 3 is specifically blocked, lipolysis increases greatly. Thus, PDE 3 is important for the in vivo regulation of the antilipolytic and lipolytic responses to hormones in human adipose tissue.
No takes yet. Share an insight, caveat, or question.
Moberg et al. (1998) studied Healthy subjects (insulin-induced hypoglycemia) (n=10). PDE 3 antagonist amrinone vs. Solvents without amrinone was evaluated on Lipolytic response after hypoglycemia (AUC of glycerol) (p=0.0001). Local perfusion with the PDE 3 antagonist amrinone increased the lipolytic response after insulin-induced hypoglycemia compared to control.
Synapse has enriched 10 related papers. Consider them for comparative context: